Bicara Therapeutics Inc. (BCAX)
NasdaqGM · Biotechnology
Scores are generated from technical indicators for educational purposes and are not a recommendation to buy or sell.
Price history
Daily closes and volumeAI Analysis Generated from the indicator readings below. Educational only.
Bicara Therapeutics Inc. is trading at $9.13, down 6.17% on the session. The 50 day average sits at $19.74 and the 200 day at $21.21, which puts the stock in a downtrend. RSI is at 17.5, which reads as oversold, and MACD is bearish crossover. Volume is volume spike.
The nearest support is around $8.36 with resistance near $17.99, so that band frames the current range. Average daily movement is roughly $1.53, or about 16.8% of the share price, which is what any stop placement has to allow for. The overall health score of 16 out of 100 combines a trend score of 0, momentum of 34 and a risk score of 18.
Technical indicators
About Bicara Therapeutics Inc.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Company website